MedTrace Logo

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

NCT06323928 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 874

Last updated 2026-04-15

No results posted yet for this study

Summary

The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.

Conditions

Interventions

DRUG

Lu AG09222

Lu AG09222 will be administered per the arm description.

DRUG

Placebo

Placebo matching to Lu AG09222 will be administered per the arm description

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Email contact via H. Lundbeck A/S · H. Lundbeck A/S

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2026-01-16
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Czechia
  • Denmark
  • France
  • Georgia
  • Germany
  • Hungary
  • Japan
  • Lithuania
  • Poland
  • Romania
  • Slovakia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06323928 on ClinicalTrials.gov